| Trial ID: | L6829 |
| Source ID: | NCT02154347
|
| Associated Drug: |
Kad-1229
|
| Title: |
Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02154347/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: KAD-1229|DRUG: Placebo|DRUG: Insulin
|
| Outcome Measures: |
Primary: Change From Baseline in HbA1c, 16 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Kissei Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
178
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: |Intervention Model: |Masking: |Primary Purpose:
|
| Start Date: |
|
| Completion Date: |
|
| Results First Posted: |
2019-09-06
|
| Last Update Posted: |
2019-09-06
|
| Locations: |
Multiple Locations, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT02154347
|
